AnaptysBio, Inc. (NASDAQ:ANAB) – Equities researchers at Wedbush boosted their FY2017 earnings per share (EPS) estimates for AnaptysBio in a report issued on Thursday. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of ($1.59) for the year, up from their previous forecast of ($1.76). Wedbush currently has a “Positive” rating and a $82.00 price target on the stock. Wedbush also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.35) EPS, Q1 2018 earnings at ($0.41) EPS, Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.50) EPS, Q4 2018 earnings at ($0.54) EPS, FY2018 earnings at ($1.90) EPS, FY2019 earnings at ($2.19) EPS, FY2020 earnings at ($2.06) EPS and FY2021 earnings at ($0.69) EPS.
Several other research firms have also recently issued reports on ANAB. Zacks Investment Research raised AnaptysBio from a “sell” rating to a “hold” rating in a research note on Friday. JMP Securities raised their target price on AnaptysBio from $45.00 to $82.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 10th. Credit Suisse Group raised their target price on AnaptysBio from $38.00 to $85.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 10th. Finally, Royal Bank Of Canada initiated coverage on AnaptysBio in a research note on Thursday, September 14th. They set an “outperform” rating and a $40.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $76.25.
TRADEMARK VIOLATION WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/11/13/wedbush-brokers-boost-earnings-estimates-for-anaptysbio-inc-anab.html.
Shares of AnaptysBio (ANAB) opened at $66.50 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.77 and a quick ratio of 10.77. AnaptysBio has a one year low of $15.17 and a one year high of $74.00.
AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.02.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ANAB. Citadel Advisors LLC purchased a new position in shares of AnaptysBio during the third quarter worth $20,406,000. Artal Group S.A. boosted its position in shares of AnaptysBio by 459.4% during the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares during the period. JPMorgan Chase & Co. boosted its holdings in AnaptysBio by 210.2% in the third quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock valued at $6,363,000 after purchasing an additional 124,219 shares during the period. Sphera Funds Management LTD. purchased a new position in AnaptysBio in the third quarter valued at $2,796,000. Finally, State of New Jersey Common Pension Fund D purchased a new position in AnaptysBio in the third quarter valued at $1,922,000. Institutional investors and hedge funds own 59.04% of the company’s stock.
In other news, major shareholder Holdings A/S Novo sold 356,300 shares of the firm’s stock in a transaction on Monday, August 21st. The stock was sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares in the company, valued at $40,862,344.40. The transaction was disclosed in a document filed with the SEC, which is available at this link.
AnaptysBio Company Profile
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
Receive News & Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.